CFSAC webinar 17 & 18 May 2016

Gemini

Senior Member
Messages
1,175
Likes
2,589
Location
East Coast USA

waiting

Senior Member
Messages
462
Likes
951
Bumping this in advance of today's session, FWIW.

Hope they'll have the sound on, this time. :(
Me, too -- but so far, it is not looking good. I can hear the Muzak on the phone but still no audio from the computer. Plus an operator just came on saying the event would begin momentarily.

I sent another email to cfsac, posing the question.
 

mango

Senior Member
Messages
905
Likes
4,985
Here's the email reply I received just now:

"We tried but could not do this. We were told last week by Verizon that it was available, but turns out we were misinformed. Next webinar we will have it available.

Our apologies.The audio version will be archived, as will be the slides."
 

Bob

Senior Member
Messages
16,455
Likes
34,056
Location
England (south coast)
Here's the email reply I received just now:

"We tried but could not do this. We were told last week by Verizon that it was available, but turns out we were misinformed. Next webinar we will have it available.

Our apologies.The audio version will be archived, as will be the slides."
Thanku mango...
At least the audio recording will be made available. That's actually better for me than having to listen to a live broadcast for 10 hours.
 

dancer

Senior Member
Messages
298
Likes
948
Location
Midwest, USA
Any other testimonies posted anywhere? Anyone listen in? Any other tidbits? I checked twitter and didn't see much. I didn't try listening in with the phone - felt too difficult today... I know the lack of webinar audio was a problem, but I was hoping for a bit of news. :)
 

Sasha

Fine, thank you
Messages
17,863
Likes
34,237
Location
UK
I just received this email from CFSAC but I've no idea why - I couldn't hear any of the meeting so I don't know what it refers to.

CFSAC said:
As follow-up to the May 18, 2016 CFSAC webinar, the following information is being provided by FDA.

On March 8, 2016, a Pharmacy Compounding Advisory Committee meeting was held. D-ribose was discussed at the meeting and was nominated for inclusion on the section 503A bulk drug substances list for use in compounding for use in the treatment of heart disease and ME/CFS.

A link to the 2016 Meeting Materials for the Pharmacy Compounding Advisory Committee meeting is below:

http://www.fda.gov/AdvisoryCommitte...acyCompoundingAdvisoryCommittee/ucm486094.htm